Anlotinib + Epirubicin (neoadjuvant)
Sources
registry, as of 2026-11-07
https://clinicaltrials.gov/api/v2/studies?query.cond=adenoid%20cystic%20carcinoma
ClinicalTrials.gov API v2, 2026-11-07: 40 active ACC-condition records; records updated since 10.20.2026 opened (raw/ctgov_new/): VMD-928 (TrkA) NCT03556228, Phase 1/2, VM Oncology, recruiting, n 242 est., PCD 2027-12, conditions list ACC; SX-682 plus docetaxel NCT07667400, Phase 1/2, NCI, includes salivary gland carcinoma, n 120 est., PCD 2036-10-01; neoadjuvant anlotinib plus epirubicin NCT07616141, Phase 2, Fudan Eye and ENT Hospital, T4 sinonasal ACC, n 76 est., PCD 2028-06-01; P-Sam NCT07162480 recruiting, PCD 2029-12-31. No ACC Phase 3 registered.
Brief source A35
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07616141
Neoadjuvant Anlotinib Combined With Epirubicin for T4 Stage Sinonasal Adenoid Cystic Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
ClinicalTrials.gov API v2 record, retrieved 2026-11-07